Cited by 688Neurogenetic and Muscular Disorders ResearchVirus-based gene therapy researchRNA Interference and Gene Delivery

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

RETRACTED ARTICLE: Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN

Open access

Foust, Kevin D, Wang, Xueyong, McGovern, Vicki L, Braun, Lyndsey, Bevan, Adam K, Haidet, Amanda M, Le, Thanh T, Morales, Pablo R, Rich, Mark M, Burghes, Arthur H M, Kaspar, Brian K·2010·Nature Biotechnology

DOI 10.1038/nbt.1610PMC PMC2889698

Open this paper in CoChat — free account

Abstract

Spinal muscular atrophy (SMA), the most common autosomal recessive neurodegenerative disease affecting children, results in impaired motor neuron function. Despite knowledge of the pathogenic role of decreased survival motor neuron (SMN) protein levels, efforts to increase SMN have not resulted in a treatment for patients. We recently demonstrated that self-complementary adeno-associated virus 9 (scAAV9) can infect approximately 60% of motor neurons when injected intravenously into neonatal mice. Here we use scAAV9-mediated postnatal day 1 vascular gene delivery to replace SMN in SMA pups and rescue motor function, neuromuscular physiology and life span. Treatment on postnatal day 5 results in partial correction, whereas postnatal day 10 treatment has little effect, suggesting a developmental period in which scAAV9 therapy has maximal benefit. Notably, we also show extensive scAAV9-mediated motor neuron transduction after injection into a newborn cynomolgus macaque. This demonstration that scAAV9 traverses the blood-brain barrier in a nonhuman primate emphasizes the clinical potential of scAAV9 gene therapy for SMA.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nbt.1610This paper is marked retracted.

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Identification and characterization of a spinal muscular atrophy-determining gene
Lefebvre, S., Bürglen, L., Reboullet, S., Clermont, O., Burlet, P., Viollet, L., Bénichou, B., Cruaud, C., Millasseau, P., Zeviani, M., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90460-3 · Cited by 3,995
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Foust, K. D., Nurre, E., Montgomery, C. L., Hernandez, A., Chan, C. M., & Kaspar, B. K. (2009) · Nature Biotechnology · doi:10.1038/nbt.1515 · Cited by 1,456
Self-citation
Clades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues
Gao, G., Vandenberghe, L. H., Alvira, M. R., Lu, Y., Calcedo, R., Zhou, X., & Wilson, J. M. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6381-6388.2004 · Cited by 1,070
The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn-/- mice and results in a mouse with spinal muscular atrophy
Monani, U. R. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.3.333 · Cited by 745
Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick?
Burghes, A. H. M., & Beattie, C. E. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2670 · Cited by 723
Self-citation
SMNΔ7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN
Le, T. T., Pham, L. T., Butchbach, M. E. R., Zhang, H. L., Monani, U. R., Coovert, D. D., Gavrilina, T. O., Xing, L., Bassell, G. J., & Burghes, A. H. M. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi078 · Cited by 600
Self-citation
Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo
McCarty, D. M., Fu, H., Monahan, P. E., Toulson, C. E., Naik, P., & Samulski, R. J. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302134 · Cited by 547
Directed evolution of adeno-associated virus yields enhanced gene delivery vectors
Maheshri, N., Koerber, J. T., Kaspar, B. K., & Schaffer, D. V. (2006) · Nature Biotechnology · doi:10.1038/nbt1182 · Cited by 538 · cited 1×
“Advances in vector design, such as AAV capsid modification, mutagenesis or gene shuffling, may expand the opportunity to target neurons in the adul”
BackgroundSelf-citation
Circular Intermediates of Recombinant Adeno-Associated Virus Have Defined Structural Characteristics Responsible for Long-Term Episomal Persistence in Muscle Tissue
Duan, D., Sharma, P., Yang, J., Yue, Y., Dudus, L., Zhang, Y., Fisher, K. J., & Engelhardt, J. F. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8568-8577.1998 · Cited by 522
Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons
Duque, S., Joussemet, B., Riviere, C., Marais, T., Dubreil, L., Douar, A.-M., Fyfe, J., Moullier, P., Colle, M.-A., & Barkats, M. (2009) · Molecular Therapy · doi:10.1038/mt.2009.71 · Cited by 511

Flagged first, then by citations

Show all 30 references

Sorted by citations

Items 401–500 of 687

Customized blood-brain barrier shuttle peptide to increase AAV9 vector crossing the BBB and augment transduction in the brain
Zhang, X., Chai, Z., Lee Dobbins, A., Itano, M. S., Askew, C., Miao, Z., Niu, H., Samulski, R. J., & Li, C. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2021.121340 · Cited by 23
Advances of Genome Editing with CRISPR/Cas9 in Neurodegeneration: The Right Path towards Therapy
Klinkovskij, A., Shepelev, M. V., Isaakyan, Y. A., Aniskin, D., & Ulasov, I. V. (2023) · Biomedicines · doi:10.3390/biomedicines11123333 · Cited by 24
Therapeutic Strategies For The Treatment Of Spinal Muscular Atrophy
Cherry, J. J., & Androphy, E. J. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.107 · Cited by 23
Disruption of snRNP biogenesis factors Tgs1 and pICln induces phenotypes that mirror aspects of SMN-Gemins complex perturbation in Drosophila, providing new insights into spinal muscular atrophy
Borg, R. M., Fenech‐Salerno, B., Vassallo, N., Bordonné, R., & Cauchi, R. J. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.06.015 · Cited by 23
Diagnosis and New Treatment Avenues in Spinal Muscular Atrophy
Kirschner, J., & Pechmann, A. (2017) · Neuropediatrics · doi:10.1055/s-0037-1603517 · Cited by 23
Minor snRNA gene delivery improves the loss of proprioceptive synapses on SMA motor neurons
Osman, E. Y., Alstyne, M. V., Yen, P., Lotti, F., Feng, Z., Ling, K., Ko, C., Pellizzoni, L., & Lorson, C. L. (2020) · JCI Insight · doi:10.1172/jci.insight.130574 · Cited by 23
Mesenchymal Stem Cell-Based Therapy in a Mouse Model of Experimental Autoimmune Encephalomyelitis (EAE)
Bowles, A. C., Scruggs, B. A., & Bunnell, B. A. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-1453-1_25 · Cited by 22
Modern approaches in gene therapy of motor neuron diseases
Zakharova, M. N. (2020) · Medicinal Research Reviews · doi:10.1002/med.21705 · Cited by 23
Gene Therapy for Parkinsons and Alzheimers Diseases: from the Bench to Clinical Trials
Nobre, R. J., & de Almeida, L. P. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211798072472 · Cited by 22
Therapy Development for Spinal Muscular Atrophy in SMN Independent Targets
Tsai, L. (2012) · Neural Plasticity · doi:10.1155/2012/456478 · Cited by 22
A Cell System for Phenotypic Screening of Modifiers of SMN2 Gene Expression and Function
Li, D. K., Tisdale, S., Espinoza‐Derout, J., Saieva, L., Lotti, F., & Pellizzoni, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071965 · Cited by 22
ML372 blocks SMN ubiquitination and improves spinal muscular atrophy pathology in mice
Abera, M. B., Xiao, J., Nofziger, J. H., Titus, S., Southall, N. T., Zheng, W., Moritz, K. E., Ferrer, M., Cherry, J. J., Androphy, E. J., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.88427 · Cited by 22
Viral vectors for neuronal cell type-specific visualization and manipulations
Liu, Y., Hegarty, S. V., Winter, C. C., Wang, F., & He, Z. (2020) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2020.03.011 · Cited by 22
Perinatal systemic gene delivery using adeno-associated viral vectors
Karda, R., Buckley, S. M. K., Mattar, C. N. Z., Ng, J., Massaro, G., Hughes, M. P., Kurian, M. A., Baruteau, J., Gissen, P., Chan, J. K. Y., et al. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00089 · Cited by 22
Genetic screening of spinal muscular atrophy using a real-time modified COP-PCR technique with dried blood-spot DNA
Rochmah, M. A., Harahap, N. I. F., Niba, E. T. E., Nakanishi, K., Awano, H., Morioka, I., Iijima, K., Saito, T., Saito, K., Lai, P. S., et al. (2017) · Brain and Development · doi:10.1016/j.braindev.2017.04.015 · Cited by 21
Translational medicine in neuromuscular disorders: from academia to industry
Cowling, B. S., & Thielemans, L. A. (2019) · Disease Models & Mechanisms · doi:10.1242/dmm.041434 · Cited by 24
Of rAAV and Men: From Genetic Neuromuscular Disorder Efficacy and Toxicity Preclinical Studies to Clinical Trials and Back
Buscara, L., Gross, D., & Danièle, N. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10040258 · Cited by 22
Comparison of Endovascular and Intraventricular Gene Therapy With Adeno-Associated Virus–α-L-Iduronidase for Hurler Disease
Janson, C. G., Romanova, L. G., Leone, P., Nan, Z., Belur, L. R., McIvor, R. S., & Low, W. C. (2013) · Neurosurgery · doi:10.1227/neu.0000000000000157 · Cited by 23
Evaluation of Peripheral Blood Mononuclear Cell Processing and Analysis for Survival Motor Neuron Protein
Kobayashi, D. T., Decker, D. E., Zaworski, P. G., Klott, K., McGonigal, J., Ghazal, N. B., Sly, L. M., Chung, B., Vanderlugt, J., & Chen, K. S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050763 · Cited by 21
Somatic Therapy of a Mouse SMA Model with a U7 snRNA Gene Correcting SMN2 Splicing
Odermatt, P., TRUEB, J., Furrer, L., Fricker, R., Marti, A., & Schümperli, D. (2016) · Molecular Therapy · doi:10.1038/mt.2016.152 · Cited by 23
Animal models for neuropsychiatric disorders: prospects for circuit intervention
Kaiser, T., Zhou, Y., & Feng, G. (2017) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2017.03.010 · Cited by 21
Gene Therapy: A Promising Approach to Treating Spinal Muscular Atrophy
Mulcahy, P. J., Iremonger, K., Karyka, E., Herranz-Martín, S., Shum, K., Tam, J. K. V., & Azzouz, M. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.186 · Cited by 20
MCOLN1 gene therapy corrects neurologic dysfunction in the mouse model of mucolipidosis IV
DeRosa, S., Salani, M., Smith, S., Sangster, M., Miller-Browne, V., Wassmer, S., Xiao, R., Vandenberghe, L. H., Slaugenhaupt, S. A., Misko, A. L., et al. (2021) · Human Molecular Genetics · doi:10.1093/hmg/ddab093 · Cited by 16
GEMINs: potential therapeutic targets for spinal muscular atrophy?
Borg, R. M., & Cauchi, R. J. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00325 · Cited by 20
Serum global metabolomics profiling reveals profound metabolic impairments in patients with MPS IIIA and MPS IIIB
Fu, H., Meadows, A. S., Pineda, R. J., Mohney, R. P., Stirdivant, S. M., & McCarty, D. M. (2017) · Metabolic Brain Disease · doi:10.1007/s11011-017-0009-1 · Cited by 20
Phosphatase and tensin homologue: a therapeutic target for SMA
Godena, V. K., & Ning, K. (2017) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2017.38 · Cited by 20
Astrocytes in Motor Neuron Diseases
Valori, C. F., Guidotti, G., Brambilla, L., & Rossi, D. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-9913-8_10 · Cited by 19
Motor unit recovery following Smn restoration in mouse models of spinal muscular atrophy
Comley, L. H., Kline, R., Thomson, A. K., Woschitz, V., Landeros, E. V., Osman, E. Y., Lorson, C. L., & Murray, L. M. (2022) · Human Molecular Genetics · doi:10.1093/hmg/ddac097 · Cited by 20
Prenatal Gene Therapy
Schwab, M. E., & MacKenzie, T. C. (2021) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000655 · Cited by 20
Early Development of Spinal Deformities in Children Severely Affected with Spinal Muscular Atrophy after Gene Therapy with Onasemnogene Abeparvovec—Preliminary Results
Soini, V., Schreiber, G., Wilken, B., & Hell, A. K. (2023) · Children · doi:10.3390/children10060998 · Cited by 19
Amyloidosis, Synucleinopathy, and Prion Encephalopathy in a Neuropathic Lysosomal Storage Disease: The CNS-Biomarker Potential of Peripheral Blood
Naughton, B. J., Duncan, F. J., Murrey, D. A., Ware, T., Meadows, A. S., McCarty, D. M., & Fu, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080142 · Cited by 19
Organ targeted prenatal gene therapy—how far are we?
Mehta, V., Abi-Nader, K. N., Waddington, S. N., & David, A. L. (2011) · Prenatal Diagnosis · doi:10.1002/pd.2787 · Cited by 19
SMA-EUROPE workshop report: opportunities and challenges in developing clinical trials for spinal muscular atrophy in Europe
Kayadjanian, N., Burghes, A. H. M., Finkel, R. S., Mercuri, E. M., Rouault, F., Schwersenz, I., & Talbot, K. (2013) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-8-44 · Cited by 19
Self-citation
Development of social systems neuroscience using macaques
Isoda, M., Noritake, A., & Ninomiya, T. (2018) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.94.020 · Cited by 19
The Dilemma of Two Innovative Therapies for Spinal Muscular Atrophy
van der Ploeg, A. T. (2017) · New England Journal of Medicine · doi:10.1056/nejme1712106 · Cited by 19
Clinical recommendations: The role of mechanisms in the GRADE framework
Perillat, L. O. M., & Mercuri, M. (2022) · Studies in History and Philosophy of Science Part A · doi:10.1016/j.shpsa.2022.08.018 · Cited by 18
Clinical and molecular features and therapeutic perspectives of spinal muscular atrophy with respiratory distress type 1
Vanoli, F., Rinchetti, P., Porro, F., Parente, V., & Corti, S. P. (2015) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12606 · Cited by 18
A high-throughput genome-wide RNAi screen identifies modifiers of survival motor neuron protein
McCormack, N. M., Abera, M. B., Arnold, E. S., Gibbs, R. M., Martin, S. E., Buehler, E. C., Chen, Y., Chen, L., Fischbeck, K. H., & Burnett, B. G. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109125 · Cited by 19
Progress in spinal muscular atrophy research
Wurster, C. D., & Petri, S. (2022) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001102 · Cited by 18
MiR34 contributes to spinal muscular atrophy and AAV9-mediated delivery of MiR34a ameliorates the motor deficits in SMA mice
Chen, T., Chang, S.-H., Wu, Y.-F., Yen, Y.-P., Hsu, F., Chen, Y., Yang, M., Hsu, H.-C., Su, Y., Wong, S.-T., et al. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.03.005 · Cited by 18
Comprehensive Comparison of AAV Purification Methods: Iodixanol Gradient Centrifugation vs. Immuno-Affinity Chromatography
Lam, A. K., Mulcrone, P. L., Frabutt, D. A., Zhang, J., Chrzanowski, M., Arisa, S., Muñoz-Melero, M., Li, X., Biswas, M., Markusic, D. M., et al. (2023) · Advances in Cell and Gene Therapy · doi:10.1155/2023/2339702 · Cited by 19
Sense in Antisense Therapy for Spinal Muscular Atrophy
MacKenzie, A. (2012) · New England Journal of Medicine · doi:10.1056/nejmcibr1114629 · Cited by 18
Nonclinical data supporting orphan medicinal product designations: lessons from rare neurological conditions
Sheean, M. E., Stoyanova-Beninska, V. V., Capovilla, G., Duarte, D. M., Hofer, M. P., Hoffmann, M., Magrelli, A., Mariz, S., Tsigkos, S., Shaili, E., et al. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.09.015 · Cited by 17
Sumoylation regulates the assembly and activity of the SMN complex
Riboldi, G. M., Faravelli, I., Kuwajima, T., Delestrée, N., Dermentzaki, G., Planell-Saguer, M. D., Rinchetti, P., Hao, L. T., Beattie, C. C., Corti, S. P., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25272-5 · Cited by 18
Gene Therapy for Rare Neurological Disorders
Flotte, T. R., & Gessler, D. J. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2543 · Cited by 20
Behavioral and electrophysiological outcomes of tissue-specific Smn knockdown in Drosophila melanogaster
Timmerman, C., & Sanyal, S. (2012) · Brain Research · doi:10.1016/j.brainres.2012.10.035 · Cited by 20
SMN is required for the maintenance of embryonic stem cells and neuronal differentiation in mice
Chang, W.-F., Xu, J., Chang, C., Yang, S., Li, H.-Y., Hsieh‐Li, H. M., Tsai, M., Wu, S., Cheng, W. T.-K., Liu, J., et al. (2014) · Brain Structure and Function · doi:10.1007/s00429-014-0743-7 · Cited by 18
Applicability of Histone Deacetylase Inhibition for the Treatment of Spinal Muscular Atrophy
Lunke, S., & El‐Osta, A. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0209-2 · Cited by 19
Advances in viral vector-based delivery systems for gene therapy: a comprehensive review
Singh, K., Jain, D., Sethi, P., Gupta, J. K., Dubey, A., Noman, A. A., lal, S., Sharma, P., & Abdallah, E. M. (2025) · 3 Biotech · doi:10.1007/s13205-025-04366-7 · Cited by 21
Genetic therapy for spinal muscular atrophy
MacKenzie, A. (2010) · Nature Biotechnology · doi:10.1038/nbt0310-235 · Cited by 17
Increasing SMN levels using the histone deacetylase inhibitor SAHA ameliorates defects in skeletal muscle microvasculature in a mouse model of severe spinal muscular atrophy
Somers, E., Rießland, M., Schreml, J., Wirth, B., Gillingwater, T. H., & Parson, S. H. (2013) · Neuroscience Letters · doi:10.1016/j.neulet.2013.03.052 · Cited by 17
Current advances in drug development in spinal muscular atrophy
Singh, P., Liew, W. K. M., & Darras, B. T. (2013) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e32836565ac · Cited by 17
Near-Complete Correction of Profound Metabolomic Impairments Corresponding to Functional Benefit in MPS IIIB Mice after IV rAAV9-hNAGLU Gene Delivery
Fu, H., Meadows, A. S., Ware, T., Mohney, R. P., & McCarty, D. M. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.12.025 · Cited by 17
Spinal Muscular Atrophy – Is Newborn Screening Too Late for Children with Two SMN2 Copies?
Schwartz, O., Kölbel, H., Blaschek, A., Gläser, D., Burggraf, S., Röschinger, W., Schara, U., Müller-Felber, W., & Vill, K. (2022) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-220789 · Cited by 17
Genetic strategies to study TDP-43 in rodents and to develop preclinical therapeutics for amyotrophic lateral sclerosis
Wang, D. B., Gitcho, M. A., Kraemer, B. C., & Klein, R. L. (2011) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2011.07803.x · Cited by 18
A Single Intravenous AAV9 Injection Mediates Bilateral Gene Transfer to the Adult Mouse Retina
Bemelmans, A., Duqué, S. I., Rivière, C., Astord, S., Desrosiers, M., Marais, T., Sahel, J., Voït, T., & Barkats, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061618 · Cited by 18
Sodium vanadate combined with l-ascorbic acid delays disease progression, enhances motor performance, and ameliorates muscle atrophy and weakness in mice with spinal muscular atrophy
Liu, H.-C., Ting, C.-H., Wen, H.-L., Tsai, L., Hsieh-Li, H.-M., Li, H., & Lin‐Chao, S. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-38 · Cited by 17
Trends on Novel Targets and Nanotechnology-Based Drug Delivery System in the Treatment of Parkinson's disease: Recent Advancement in Drug Development
Majumdar, M., & Badwaik, H. R. (2024) · Current Drug Targets · doi:10.2174/0113894501312703240826070530 · Cited by 16
Restoring Protein Expression in Neuromuscular Conditions: A Review Assessing the Current State of Exon Skipping/Inclusion and Gene Therapies for Duchenne Muscular Dystrophy and Spinal Muscular Atrophy
Sheikh, O., & Yokota, T. (2021) · BioDrugs · doi:10.1007/s40259-021-00486-7 · Cited by 17
Survival motor neuron deficiency slows myoblast fusion through reduced myomaker and myomixer expression
McCormack, N. M., Villalón, E., Viollet, C., Soltis, A. R., Dalgard, C. L., Lorson, C. L., & Burnett, B. G. (2021) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12740 · Cited by 18
Gene Therapy: The View from NCATS
Brooks, P. J., Yang, N. N., & Austin, C. P. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.29018.pjb · Cited by 16
Intravenous administration of scAAV9-Hexb normalizes lifespan and prevents pathology in Sandhoff disease mice
Niemir, N., Rouvière, L., Besse, A., Vanier, M. T., Dmytrus, J., Marais, T., Astord, S., Puech, J.-P., Panasyuk, G., Cooper, J. D., et al. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy012 · Cited by 16
Gene therapies for axonal neuropathies: Available strategies, successes to date, and what to target next
Morelli, K. H., Hatton, C. L., Harper, S. Q., & Burgess, R. W. (2020) · Brain Research · doi:10.1016/j.brainres.2020.146683 · Cited by 16
From iPS Cells to Rodents and Nonhuman Primates: Filling Gaps in Modeling Parkinson's Disease
Outeiro, T. F., Heutink, P., Bézard, E., & Cenci, M. A. (2020) · Movement Disorders · doi:10.1002/mds.28387 · Cited by 16
Gene Therapy Approaches to Treat the Neurodegeneration and Visual Failure in Neuronal Ceroid Lipofuscinoses
Holthaus, S.-M. K., Smith, A. J., Mole, S., & Ali, R. R. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-75402-4_12 · Cited by 16
Improved gene delivery to adult mouse spinal cord through the use of engineered hybrid adeno-associated viral serotypes
Siu, J. J., Queen, N. J., Huang, W., Yin, F., Liu, X., Wang, C., McTigue, D. M., & Cao, L. (2017) · Gene Therapy · doi:10.1038/gt.2017.27 · Cited by 17
Evidence for Contribution of CD4+CD25+ Regulatory T Cells in Maintaining Immune Tolerance to Human Factor IX following Perinatal Adenovirus Vector Delivery
Nivsarkar, M. S., Buckley, S. M. K., Parker, A. L., Perocheau, D. P. B., McKay, T. R., Rahim, A. A., Howe, S. J., & Waddington, S. N. (2015) · Journal of Immunology Research · doi:10.1155/2015/397879 · Cited by 14
Genetic animal models of Tourette syndrome: The long and winding road from lab to clinic
Cauchi, R. J., & Tárnok, Z. (2012) · Translational Neuroscience · doi:10.2478/s13380-012-0020-2 · Cited by 14
Piggybacking on the Cholera Toxin: Identification of a CTB-Binding Protein as an Approach for Targeted Delivery of Proteins to Motor Neurons
Balmforth, M. R., Haigh, J., Kumar, V., Dai, W., Tiede, C., Tomlinson, D. C., Deuchars, J., Webb, M. E., & Turnbull, W. B. (2021) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.1c00373 · Cited by 14
Developing therapies for spinal muscular atrophy
Wertz, M. H., & Şahin, M. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12813 · Cited by 14
Stem Cell Models and Gene Targeting for Human Motor Neuron Diseases
Karpe, Y., Chen, Z.-Y., & Li, X.-J. (2021) · Pharmaceuticals · doi:10.3390/ph14060565 · Cited by 17
Molecular Pathogenesis and New Therapeutic Dimensions for Spinal Muscular Atrophy
López‐Cortés, A., Echeverría‐Garcés, G., & Ramos-Medina, M. J. (2022) · Biology · doi:10.3390/biology11060894 · Cited by 16
Pharmacotherapy for Spinal Muscular Atrophy in Babies and Children: A Review of Approved and Experimental Therapies
Chiriboga, C. A. (2022) · Pediatric Drugs · doi:10.1007/s40272-022-00529-8 · Cited by 14
Double administration of self-complementary AAV9NDUFS4 prevents Leigh disease in Ndufs4−/− mice
Corrà, S., Cerutti, R., Balmaceda, V., Viscomi, C. F., & Zeviani, M. (2022) · Brain · doi:10.1093/brain/awac182 · Cited by 15
Drug Discovery and Development for Spinal Muscular Atrophy: Lessons from Screening Approaches and Future Challenges for Clinical Development
Pruss, R. M., Giraudon‐Paoli, M., Morozova, S., Berna, P. P., Abitbol, J., & Bordet, T. (2010) · Future Medicinal Chemistry · doi:10.4155/fmc.10.228 · Cited by 14
SMN Blood Levels in a Porcine Model of Spinal Muscular Atrophy
Iyer, C. C., Wang, X., Renusch, S. R., Duqué, S. I., Wehr, A. M., Mo, X.-M., McGovern, V. L., Arnold, W. D., Burghes, A. H. M., & Kolb, S. J. (2017) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-170209 · Cited by 14
Self-citation
Envisioning treating genetically-defined urinary tract malformations with viral vector-mediated gene therapy
Lopes, F. M., Woolf, A. S., & Roberts, N. A. (2021) · Journal of Pediatric Urology · doi:10.1016/j.jpurol.2021.07.002 · Cited by 11
Systematic review and meta-analysis determining the benefits of in vivo genetic therapy in spinal muscular atrophy rodent models
Chilcott, E. M., Muiruri, E. W., Hirst, T. C., & Yáñez‐Muñoz, R. J. (2021) · Gene Therapy · doi:10.1038/s41434-021-00292-4 · Cited by 17
Deletion of atrophy enhancing genes fails to ameliorate the phenotype in a mouse model of spinal muscular atrophy
Iyer, C. C., McGovern, V. L., Wise, D. O., Glass, D. J., & Burghes, A. H. M. (2014) · Neuromuscular Disorders · doi:10.1016/j.nmd.2014.02.007 · Cited by 13
Self-citation
Recent Advances in Fetal Gene Therapy
Buckley, S. M. K., Rahim, A. A., Chan, J. K. Y., David, A. L., Peebles, D., Coutelle, C., & Waddington, S. N. (2011) · Therapeutic Delivery · doi:10.4155/tde.11.17 · Cited by 13
High-resolution melting (HRM) analysis as a feasible method for detecting spinal muscular atrophy via dried blood spots
Er, T., Kan, T.-M., Su, Y.-F., Liu, T., Chang, J., Hung, S., & Jong, Y. (2012) · Clinica Chimica Acta · doi:10.1016/j.cca.2012.06.033 · Cited by 13
Engineering a gene silencing viral construct that targets the cat hypothalamus to induce permanent sterility: An update
Dissen, G. A., Adachi, K., Lomniczi, A., Chatkupt, T. T., Davidson, B. L., Nakai, H., & Ojeda, S. (2016) · Reproduction in Domestic Animals · doi:10.1111/rda.12834 · Cited by 13
Motor Neuron Biology and Disease: A Current Perspective on Infantile-Onset Spinal Muscular Atrophy
Jha, N. N., Kim, J.-K., & Monani, U. R. (2018) · Future Neurology · doi:10.2217/fnl-2018-0008 · Cited by 13
New pharmacotherapies for genetic neuromuscular disorders: opportunities and challenges
Ricci, F., Vacchetti, M., Brusa, C., Vercelli, L., Davico, C., Vitiello, B., & Mongini, T. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1634543 · Cited by 14
Functional characterization of SMN evolution in mouse models of SMA
Osman, E. Y., Bolding, M., Villalón, E., Kaifer, K. A., Lorson, Z. C., Tisdale, S., Hao, Y., Conant, G. C., Pires, J. C., Pellizzoni, L., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-45822-8 · Cited by 13
What Genetics Has Told Us and How It Can Inform Future Experiments for Spinal Muscular Atrophy, a Perspective
Blatnik, A. J., McGovern, V. L., & Burghes, A. H. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168494 · Cited by 11
Self-citation
Normalization of Patient-Identified Plasma Biomarkers in SMNΔ7 Mice following Postnatal SMN Restoration
Arnold, W. D., Duqué, S. I., Iyer, C. C., Zaworski, P. G., McGovern, V. L., Taylor, S. J., von Herrmann, K. M., Kobayashi, D. T., Chen, K. S., Kolb, S. J., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0167077 · Cited by 13
Self-citation
Neuromuscular denervation and deafferentation but not motor neuron death are disease features in the Smn2B/- mouse model of SMA
Carlini, M. J., Triplett, M. K., & Pellizzoni, L. (2022) · PLoS ONE · doi:10.1371/journal.pone.0267990 · Cited by 11
Adeno‐Associated Virus‐Encapsulated Alginate Microspheres Loaded in Collagen Gel Carriers for Localized Gene Transfer
Kurashina, Y., Kurihara, S., Kubota, T., Takatsuka, S., Hirabayashi, M., Shimmura, H., Miyahara, H., Hioki, A., Matsushita, Y., Muramatsu, J., et al. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202303546 · Cited by 14
Spinal Muscular Atrophy (SMA): Treatment strategies, challenges and future prospects
Mishra, N. K., & Mishra, A. (2025) · Pharmacological Research - Reports · doi:10.1016/j.prerep.2025.100031 · Cited by 14
Nucleic Acid-Based Therapeutic Approach for Spinal and Bulbar Muscular Atrophy and Related Neurological Disorders
Hirunagi, T., Sahashi, K., Meilleur, K. G., & Katsuno, M. (2022) · Genes · doi:10.3390/genes13010109 · Cited by 13
RNA-Processing Dysfunction in Spinal Muscular Atrophy
Tisdale, S., & Pellizzoni, L. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803685-3.00007-0 · Cited by 11
Rewriting the (tran)script: Application to spinal muscular atrophy
Ratni, H., Mueller, L. A., & Ebeling, M. (2019) · Progress in medicinal chemistry · doi:10.1016/bs.pmch.2018.12.003 · Cited by 12
Targeting the Root Cause of Mucopolysaccharidosis IIIA with a New scAAV9 Gene Replacement Vector
Bobo, T. A., Samowitz, P. N., Robinson, M. I., & Fu, H. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.10.014 · Cited by 11
Novel Therapies for Spinal Muscular Atrophy are Likely Changing the Patient Phenotype.
Vu-Han, T.-L., Weiss, C., & Pumberger, M. (2020) · The spine journal · doi:10.1016/j.spinee.2020.08.013 · Cited by 8
Investigating Immune Responses to the scAAV9-HEXM Gene Therapy Treatment in Tay–Sachs Disease and Sandhoff Disease Mouse Models
Kot, S., Karumuthil‐Melethil, S., Woodley, E., Zaric, V., Thompson, P., Chen, Z., Lykken, E. A., Keimel, J. G., Kaemmerer, W. F., Gray, S. J., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136751 · Cited by 13
In utero gene transfer to the mouse nervous system
Rahim, A. A., Wong, A. M. S., Buckley, S. M. K., Chan, J. K. Y., David, A. L., Cooper, J. D., Coutelle, C. C., Peebles, D., & Waddington, S. N. (2010) · Biochemical Society Transactions · doi:10.1042/bst0381489 · Cited by 11
Generation and validation of novel adeno-associated viral vectors for the analysis of Ca2+ homeostasis in motor neurons
Norante, R. P., Massimino, M. L., Lorenzon, P., Mario, A. D., Peggion, C., Vicario, M., Albiero, M., Sorgato, M. C., Lopreiato, R., & Bertoli, A. (2017) · Scientific Reports · doi:10.1038/s41598-017-06919-0 · Cited by 11
Gene therapy successes point to better therapies
Dolgin, E. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1918306116 · Cited by 11
Viral-Mediated Gene Replacement Therapy in the Developing Central Nervous System: Current Status and Future Directions
Uchitel, J., Kantor, B., Smith, E. C., & Mikati, M. A. (2020) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2020.04.010 · Cited by 11

Authors: Foust, K. D., Wang, X., McGovern, V. L., Braun, L., Bevan, A. K., Haidet, A. M., Le, T. T., Morales, P. R., Rich, M. M., Burghes, A. H. M., & Kaspar, B. K.
Affiliations: Nationwide Children's Hospital (US)
Wright State University (US)
The Ohio State University (US)
Corresponding author: Kaspar, Brian K
ORCID: Foust, Kevin D
Wang, Xueyong
McGovern, Vicki L
Le, Thanh T
Morales, Pablo R
Rich, Mark M
Burghes, Arthur H M
Kaspar, Brian K
Venue: Nature Biotechnology
Publisher: Springer Science and Business Media LLC
Published: 2010-02-28
Volume: 28
Issue: 3
Pages: 271-274
ISSN: 0733-222X (ISSN-L)
1087-0156
1546-1696
DOI: 10.1038/nbt.1610
PMC: PMC2889698
OpenAlex: W2045117117
Cited by: 688
References: 30
Citations by year: 2026: 5 · 2025: 10 · 2024: 17 · 2023: 19 · 2022: 42 · 2021: 49 · 2020: 61 · 2019: 51 · 2018: 32 · 2017: 56 · 2016: 48 · 2015: 51 · 2014: 57 · 2013: 54 · 2012: 48
FWCI: 27.28
Type: journal article
Language: en
Status: Retracted
Update notices: retraction (2022-10-06)
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature Biotechnology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
CORE Scholar (Wright State University) (submittedVersion)
Journal of Bioresource Management (submittedVersion)
Funders: National Institute of Neurological Disorders and Stroke (R21NS064328, RC2NS069476, P30NS045758, P01NS057228, R01NS038650, F31NS058224)
Topics: Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords: spinal muscular atrophy, gene therapy, motor neurons, blood-brain barrier, cynomolgus macaques, mouse model, retraction
MeSH terms: Dependovirus, Animals, Animals, Newborn, Disease Models, Animal, Macaca fascicularis, Male, Mice, Transgenic, Microscopy, Fluorescence, Motor Neurons, Muscular Atrophy, Spinal, Phenotype, Gene Transfer Techniques, Green Fluorescent Proteins, Mice, Kaplan-Meier Estimate, Survival of Motor Neuron 1 Protein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

RETRACTED ARTICLE: Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks